Spironolactone (S) alone or with furosemide (F) in the treatment ofascites in nonazotemic cirrhosis

BackgroundApproximately 20% of people with cirrhosis develop ascites. Several di erent treatments are available; including, among others, paracentesis plus fluid replacement, transjugular intrahepatic portosystemic shunts, aldosterone antagonists, and loop diuretics. However, there is uncertainty surrounding their relative e icacy. ObjectivesTo compare the benefits and harms of di erent treatments for ascites in people with decompensated liver cirrhosis through a network meta-analysis and to generate rankings of the di erent treatments for ascites according to their safety and e icacy. Search methodsWe searched CENTRAL, MEDLINE, Embase, Science Citation Index Expanded, World Health Organization International Clinical Trials Registry Platform, and trials registers until May 2019 to identify randomised clinical trials in people with cirrhosis and ascites. Selection criteriaWe included only randomised clinical trials (irrespective of language, blinding, or status) in adults with cirrhosis and ascites. We excluded randomised clinical trials in which participants had previously undergone liver transplantation. Data collection and analysisWe performed a network meta-analysis with OpenBUGS using Bayesian methods and calculated the odds ratio, rate ratio, and hazard ratio (HR) with 95% credible intervals (CrI) based on an available-case analysis, according to National Institute of Health and Care Excellence Decision Support Unit guidance.Treatment for ascites in adults with decompensated liver cirrhosis: a network meta-analysis (Review)

show abstract

Treatment for ascites in adults with decompensated liver cirrhosis: a network meta-analysis

Benmassaoud

Freeman

Roccarina

et al. 2020

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

show abstract

Multicenter hospital study on prescribing patterns for prophylaxis and treatment of complications of cirrhosis

Lucena

Andrade

Tognoni

et al. 2002

European Journal of Clinical Pharmacology

View full text Add to dashboard Cite

show abstract

Pathophysiology, diagnosis and treatment of ascites in cirrhosis

Úriz

Cárdenas

Arroyo

2000

Best Practice & Research Clinical Gastroenterology

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Spironolactone (S) alone or with furosemide (F) in the treatment ofascites in nonazotemic cirrhosis

Cited by 3 publications

References 0 publications

Treatment for ascites in adults with decompensated liver cirrhosis: a network meta-analysis

Treatment for ascites in adults with decompensated liver cirrhosis: a network meta-analysis

Multicenter hospital study on prescribing patterns for prophylaxis and treatment of complications of cirrhosis

Pathophysiology, diagnosis and treatment of ascites in cirrhosis

Contact Info

Product

Resources

About